Protocols
24 protocol(s) meet the specified criteria
Disease Site: Myeloid and Monocytic Leukemia
Protocol No.TitleStatus
10-CBAA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indicationsOpen
A-TREATAmerican Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT) Open
AAML1031A Phase III Randomized Trial for Patients with de novo AML using Bortezomib(IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITDOpen
AAML1531Risk-stratified Therapy for Acute Myeloid Leukemia in Down SyndromeOpen
ACCL1131A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)Open
BMT-CTN-1102A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic SyndromeOpen
CC-5013-AML-002A Phase 2, Multicenter, Single-Arm, Openlabel Study to Evaluate the Activity, Safety and Pharmacokinetics Of Lenalidomide (Revlimid®) In Pediatric Subjects from 1 To ≤ 18 Years Of Age With Relapsed or Refractory Acute Myeloid Leukemia Open
COGAAML08B1Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)Open
CP-MGD006-01A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia Open
H3B-8800-G000-101An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic LeukemiaOpen
J1651Phase 2 Study of Azacitidine (AZA) in Combination with Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (>65 Years) AML PatientsOpen
LCCC0824Tissue Procurement For Hematolymphoid ConditionsOpen
LCCC0905Graft-Versus-Host Disease Solid Tissue ProcurementOpen
LCCC1241Complementary and Alternative medicine use at UNC clinicsOpen
LCCC1432Longitudinal Assessment of Symptoms, Functional Status, and Quality of Life in Adults with Acute Myeloid LeukemiaOpen (affiliates only)
LCCC1522Phase 2 Study of High Dose Cytarabine Followed by Pembrolizumab in Relapsed and Refractory Acute Myeloid Leukemia Open
LCCC1535Understanding Treatment Decision-making and Psychological Distress in Patients with Advanced CancerOpen
LCCC1542Leukemia Specific Splice Isoforms as Neo-Antigens for T-cell Immunotherapy Open
LCCC1702Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in Acute Myeloid Leukemia (AML) patients in remission following Allogeneic Stem Cell Transplant or Induction and Consolidation ChemotherapyOpen
LCCC1704Assessing the Feasibility of Screening and Treating Anxiety and Depression in the Bone Marrow Transplant PopulationOpen
LCCC1726Randomized Placebo Controlled Trial of High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell TransplantationOpen
LTE1401Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic MalignanciesOpen
TPI-ALV-101A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)Open
TPI-ALV-201A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)Open